Growth Metrics

Genmab A (GMAB) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $1.4 billion.

  • Genmab A's Total Current Liabilities rose 9180.11% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 9180.11%. This contributed to the annual value of $1.4 billion for FY2025, which is 9180.11% up from last year.
  • As of Q4 2025, Genmab A's Total Current Liabilities stood at $1.4 billion, which was up 9180.11% from $741.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Total Current Liabilities ranged from a high of $1.4 billion in Q4 2025 and a low of $368.0 million during Q4 2023
  • Over the past 3 years, Genmab A's median Total Current Liabilities value was $741.0 million (recorded in 2025), while the average stood at $781.8 million.
  • As far as peak fluctuations go, Genmab A's Total Current Liabilities surged by 10217.39% in 2024, and later skyrocketed by 9180.11% in 2025.
  • Over the past 3 years, Genmab A's Total Current Liabilities (Quarter) stood at $368.0 million in 2023, then surged by 102.17% to $744.0 million in 2024, then surged by 91.8% to $1.4 billion in 2025.
  • Its Total Current Liabilities stands at $1.4 billion for Q4 2025, versus $741.0 million for Q3 2025 and $629.0 million for Q2 2025.